Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy

Cara Rabik, Maria Chidiamara Njoku, M. Eileen Dolan

Research output: Contribution to journalReview article

Abstract

DNA adducts at the O6-position of guanine are a result of the carcinogenic, mutagenic and cytotoxic actions of methylating and chloroethylating agents. The presence of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) renders cells resistant to the biological effects induced by agents that attack at this position. O6-Benzylguanine (O6-BG) is a low molecular weight substrate of AGT and therefore, results in sensitizing cells and tumors to alkylating agent-induced cytotoxicity and antitumor activity. Presently, chemotherapy regimens of O6-BG in combination with BCNU, temozolomide and Gliadel are in clinical development. Other ongoing clinical trials include expression of mutant AGT proteins that confer resistance to O6-BG in bone marrow stem cells, in an effort to reduce the potential enhanced toxicity and mutagenicity of alkylating agents in the bone marrow. O6-BG has also been found to enhance the cytotoxicity of agents that do not form adducts at the O6-position of DNA, including platinating agents. O6-BG's mechanism of action with these agents is not fully understood; however, it is independent of AGT activity or AGT inactivation. A better understanding of the effects of this agent will contribute to its clinical usefulness and the design of better analogs to further improve cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)261-276
Number of pages16
JournalCancer Treatment Reviews
Volume32
Issue number4
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Drug Therapy
Alkylating Agents
temozolomide
Carmustine
DNA Adducts
Guanine
Mutant Proteins
DNA Repair
Bone Marrow Cells
Neoplasms
Stem Cells
Molecular Weight
Bone Marrow
Clinical Trials
O(6)-benzylguanine
DNA alkyltransferase
DNA
Proteins
poliferprosan 20 drug combination carmustine

Keywords

  • Alkylation
  • Alkyltransferase
  • Chemotherapy
  • DNA repair
  • O-benzylguanine
  • Platination

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. / Rabik, Cara; Njoku, Maria Chidiamara; Dolan, M. Eileen.

In: Cancer Treatment Reviews, Vol. 32, No. 4, 01.06.2006, p. 261-276.

Research output: Contribution to journalReview article

Rabik, Cara ; Njoku, Maria Chidiamara ; Dolan, M. Eileen. / Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. In: Cancer Treatment Reviews. 2006 ; Vol. 32, No. 4. pp. 261-276.
@article{5d51c45012284b04add9d01c508727b1,
title = "Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy",
abstract = "DNA adducts at the O6-position of guanine are a result of the carcinogenic, mutagenic and cytotoxic actions of methylating and chloroethylating agents. The presence of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) renders cells resistant to the biological effects induced by agents that attack at this position. O6-Benzylguanine (O6-BG) is a low molecular weight substrate of AGT and therefore, results in sensitizing cells and tumors to alkylating agent-induced cytotoxicity and antitumor activity. Presently, chemotherapy regimens of O6-BG in combination with BCNU, temozolomide and Gliadel are in clinical development. Other ongoing clinical trials include expression of mutant AGT proteins that confer resistance to O6-BG in bone marrow stem cells, in an effort to reduce the potential enhanced toxicity and mutagenicity of alkylating agents in the bone marrow. O6-BG has also been found to enhance the cytotoxicity of agents that do not form adducts at the O6-position of DNA, including platinating agents. O6-BG's mechanism of action with these agents is not fully understood; however, it is independent of AGT activity or AGT inactivation. A better understanding of the effects of this agent will contribute to its clinical usefulness and the design of better analogs to further improve cancer chemotherapy.",
keywords = "Alkylation, Alkyltransferase, Chemotherapy, DNA repair, O-benzylguanine, Platination",
author = "Cara Rabik and Njoku, {Maria Chidiamara} and Dolan, {M. Eileen}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.ctrv.2006.03.004",
language = "English (US)",
volume = "32",
pages = "261--276",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy

AU - Rabik, Cara

AU - Njoku, Maria Chidiamara

AU - Dolan, M. Eileen

PY - 2006/6/1

Y1 - 2006/6/1

N2 - DNA adducts at the O6-position of guanine are a result of the carcinogenic, mutagenic and cytotoxic actions of methylating and chloroethylating agents. The presence of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) renders cells resistant to the biological effects induced by agents that attack at this position. O6-Benzylguanine (O6-BG) is a low molecular weight substrate of AGT and therefore, results in sensitizing cells and tumors to alkylating agent-induced cytotoxicity and antitumor activity. Presently, chemotherapy regimens of O6-BG in combination with BCNU, temozolomide and Gliadel are in clinical development. Other ongoing clinical trials include expression of mutant AGT proteins that confer resistance to O6-BG in bone marrow stem cells, in an effort to reduce the potential enhanced toxicity and mutagenicity of alkylating agents in the bone marrow. O6-BG has also been found to enhance the cytotoxicity of agents that do not form adducts at the O6-position of DNA, including platinating agents. O6-BG's mechanism of action with these agents is not fully understood; however, it is independent of AGT activity or AGT inactivation. A better understanding of the effects of this agent will contribute to its clinical usefulness and the design of better analogs to further improve cancer chemotherapy.

AB - DNA adducts at the O6-position of guanine are a result of the carcinogenic, mutagenic and cytotoxic actions of methylating and chloroethylating agents. The presence of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) renders cells resistant to the biological effects induced by agents that attack at this position. O6-Benzylguanine (O6-BG) is a low molecular weight substrate of AGT and therefore, results in sensitizing cells and tumors to alkylating agent-induced cytotoxicity and antitumor activity. Presently, chemotherapy regimens of O6-BG in combination with BCNU, temozolomide and Gliadel are in clinical development. Other ongoing clinical trials include expression of mutant AGT proteins that confer resistance to O6-BG in bone marrow stem cells, in an effort to reduce the potential enhanced toxicity and mutagenicity of alkylating agents in the bone marrow. O6-BG has also been found to enhance the cytotoxicity of agents that do not form adducts at the O6-position of DNA, including platinating agents. O6-BG's mechanism of action with these agents is not fully understood; however, it is independent of AGT activity or AGT inactivation. A better understanding of the effects of this agent will contribute to its clinical usefulness and the design of better analogs to further improve cancer chemotherapy.

KW - Alkylation

KW - Alkyltransferase

KW - Chemotherapy

KW - DNA repair

KW - O-benzylguanine

KW - Platination

UR - http://www.scopus.com/inward/record.url?scp=33746871832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746871832&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2006.03.004

DO - 10.1016/j.ctrv.2006.03.004

M3 - Review article

C2 - 16698182

AN - SCOPUS:33746871832

VL - 32

SP - 261

EP - 276

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 4

ER -